Transtech Pharma, Inc.

Vtv Therapeutics LLC

Christopher Behme

Adnan M M Mjalli

Dharma Rao Polisetti

Mustafa Guzel

Stephen Thomas Davis

Thomas Scott Yokum

Kalpathy Chidambareswaran Santhosh

Robert Carl Andrews

Daniel Peter Christen

Muralidhar Bondlela

Devi Reddy Gohimukkula

Ravindra Reddy Yarragunta

Jennifer L R Freeman

James C Quada, Jr

Guoxiang Huang

Robert Rothlein

Xiao-Chuan Guo

Devi Reddy Gohimmukkula

Sameer Tyagi

Santhosh Kalpathy

Tripura Yaramasu

Adnan Mm Mjalli

James Quada

Jennifer LR Freeman

Adnan MM Mjalli

Daniel P Christen

The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial.

Substituted azoanthracene derivatives and intermediates for preparation thereof

The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R, R, R, Rand Rare as herein described, and wherein said methods of use include uses for the treatment of disorders and diseases, such as diabetes.

Oxadiazoanthracene compounds for the treatment of diabetes

The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.

Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

The present invention provides methods of synthesizing oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R, R, R, Rand Rare as herein described, and methods of synthesizing precursors to these oxadiazoanthracene derivatives.

The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R, R, R, Rand Rare as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.

The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R, R, R, Rand Rare as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).

This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be useful for inhibiting the intrinsic pathway of blood coagulation. The compounds may be useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway.

Aryl and heteroaryl compounds, compositions, and methods of use

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists, or more preferably, partial antagonist of factor IX and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds are useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX. Such diseases or disease states include stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures, long periods of confinement, and acquired or inherited pro-coagulant states.

Aryl and heteroaryl compounds and methods to modulate coagulation

Growing community of inventors

Jamestown, NC, United States of America

Christopher Behme